Abstract
Exogenous IgE acts as an adjuvant in tumor vaccination in mice, and therefore a direct role of endogenous IgE in tumor immunosurveillance was investigated. By using genetically engineered mice, we found that IgE ablation rendered mice more susceptible to the growth of transplantable tumors. Conversely, a strengthened IgE response provided mice with partial or complete resistance to tumor growth, depending on the tumor type. By genetic crosses, we showed that IgE-mediated tumor protection was mostly lost in mice lacking FceRI. Tumor protection was also lost after depletion of CD8+ T cells, highlighting a cross-Talk between IgE and T cell- mediated tumor immunosurveillance. Our findings provide the rationale for clinical observations that relate atopy with a lower risk for developing cancer and open new avenues for the design of immunotherapeutics relevant for clinical oncology. The Journal of Immunology, 2016, 197: 2583-2588.
| Original language | English |
|---|---|
| Pages (from-to) | 2583-2588 |
| Number of pages | 6 |
| Journal | Journal of Immunology |
| Volume | 197 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Oct 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Immunology
Cite this
Cutting edge : IgE plays an active role in tumor immunosurveillance in mice. / Nigro, Elisa Agnese; Brini, Anna Teresa; Yenagi, Vijay A.; Ferreira, Lorena Maria; Achatz-Straussberger, Gertrude; Ambrosi, Alessandro; Sanvito, Francesca; Soprana, Elisa; Van Anken, Eelco; Achatz, Gernot; Siccardi, Antonio G.; Vangelista, Luca.
In: Journal of Immunology, Vol. 197, No. 7, 01.10.2016, p. 2583-2588.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cutting edge
T2 - IgE plays an active role in tumor immunosurveillance in mice
AU - Nigro, Elisa Agnese
AU - Brini, Anna Teresa
AU - Yenagi, Vijay A.
AU - Ferreira, Lorena Maria
AU - Achatz-Straussberger, Gertrude
AU - Ambrosi, Alessandro
AU - Sanvito, Francesca
AU - Soprana, Elisa
AU - Van Anken, Eelco
AU - Achatz, Gernot
AU - Siccardi, Antonio G.
AU - Vangelista, Luca
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Exogenous IgE acts as an adjuvant in tumor vaccination in mice, and therefore a direct role of endogenous IgE in tumor immunosurveillance was investigated. By using genetically engineered mice, we found that IgE ablation rendered mice more susceptible to the growth of transplantable tumors. Conversely, a strengthened IgE response provided mice with partial or complete resistance to tumor growth, depending on the tumor type. By genetic crosses, we showed that IgE-mediated tumor protection was mostly lost in mice lacking FceRI. Tumor protection was also lost after depletion of CD8+ T cells, highlighting a cross-Talk between IgE and T cell- mediated tumor immunosurveillance. Our findings provide the rationale for clinical observations that relate atopy with a lower risk for developing cancer and open new avenues for the design of immunotherapeutics relevant for clinical oncology. The Journal of Immunology, 2016, 197: 2583-2588.
AB - Exogenous IgE acts as an adjuvant in tumor vaccination in mice, and therefore a direct role of endogenous IgE in tumor immunosurveillance was investigated. By using genetically engineered mice, we found that IgE ablation rendered mice more susceptible to the growth of transplantable tumors. Conversely, a strengthened IgE response provided mice with partial or complete resistance to tumor growth, depending on the tumor type. By genetic crosses, we showed that IgE-mediated tumor protection was mostly lost in mice lacking FceRI. Tumor protection was also lost after depletion of CD8+ T cells, highlighting a cross-Talk between IgE and T cell- mediated tumor immunosurveillance. Our findings provide the rationale for clinical observations that relate atopy with a lower risk for developing cancer and open new avenues for the design of immunotherapeutics relevant for clinical oncology. The Journal of Immunology, 2016, 197: 2583-2588.
UR - http://www.scopus.com/inward/record.url?scp=84989823879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84989823879&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1601026
DO - 10.4049/jimmunol.1601026
M3 - Article
VL - 197
SP - 2583
EP - 2588
JO - Journal of Immunology
JF - Journal of Immunology
SN - 0022-1767
IS - 7
ER -